* Lipocine Inc LPCN.OQ LPCN.O is expected to show a fall
in
quarterly revenue when it reports results on May 9 (estimated)
for the period ending March 31 2024
*
* LSEG's mean analyst estimate for Lipocine Inc is for a
loss
of 68 cents per share.
* The one available analyst rating on the shares is "strong
buy".
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Lipocine
Inc is
$33.00, above its last closing price of $4.92.
This summary was machine generated May 7 at 18:32 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)